文献速递神经肿瘤

Oct4A棕榈酰化调节人胶质母细胞瘤细胞的致瘤性与干性

Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells.
PubMed 文献 · Neuro Oncol · 2023-01-01

研究检测脑肿瘤细胞系与组织中Oct4变体表达,发现三种变体均表达于不同类型脑癌,Oct4A对维持胶质瘤干细胞致瘤性重要。ZDHHC17介导的棕榈酰化保护Oct4A免于溶酶体降解以维持蛋白稳定性,并促进Sox4与Oct4A整合于SOX2增强子亚区以维持干细胞性能。设计的Oct4A棕榈酰化竞争性抑制剂可抑制胶质瘤干细胞自我更新与致瘤性。

要点

  • Oct4A对维持胶质瘤干细胞致瘤性重要。
  • ZDHHC17介导的棕榈酰化保护Oct4A免于溶酶体降解以维持蛋白稳定性。
  • Oct4A棕榈酰化竞争性抑制剂抑制胶质瘤干细胞自我更新与致瘤性。

核心结论

  • Oct4A作用于胶质母细胞瘤的致瘤活性,Oct4A棕榈酰化是候选治疗靶点。

研究设计与样本

  • 评估脑癌细胞系与脑肿瘤组织中Oct4变体表达,采用定量实时PCR、蛋白质印迹和免疫组化分析。
  • 采用酰基-生物素交换法测定Oct4A棕榈酰化水平,并通过体外实验(神经球形成实验、双重免疫荧光、药物治疗、荧光素酶实验和免疫共沉淀)及体内实验(异种移植模型)研究棕榈酰化Oct4A对胶质瘤干细胞的影响。

主要发现

  • 三种Oct4变体均表达于不同类型脑癌,Oct4A对维持胶质瘤干细胞致瘤性重要。
  • ZDHHC17介导的棕榈酰化对保护Oct4A免于溶酶体降解以维持其蛋白稳定性不可或缺。
  • Oct4A棕榈酰化有助于将Sox4与Oct4A整合于SOX2增强子亚区以维持胶质瘤干细胞的干细胞性能。
  • 设计的Oct4A棕榈酰化竞争性抑制剂抑制胶质瘤干细胞的自我更新能力与致瘤性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma multiforme and other solid malignancies are heterogeneous, containing subpopulations of tumor cells that exhibit stem characteristics. Oct4, also known as POU5F1, is a key transcription factor in the self-renewal, proliferation, and differentiation of stem cells. Although it has been detected in advanced gliomas, the biological function of Oct4, and transcriptional machinery maintained by the stemness of Oct4 protein-mediated glioma stem cells (GSC), has not been fully determined. METHODS: The expression of Oct4 variants was evaluated in brain cancer cell lines, and in brain tumor tissues, by quantitative real-time PCR, western blotting, and immunohistochemical analysis. The palmitoylation level of Oct4A was determined by the acyl-biotin exchange method, and the effects of palmitoylation Oct4A on GSCs were investigated by a series of in vitro (neuro-sphere formation assay, double immunofluorescence, pharmacological treatment, luciferase assay, and coimmunoprecipitation) and in vivo (xenograft model) experiments. RESULTS: Here, we report that all three variants of Oct4 are expressed in different types of cerebral cancer, while Oct4A is important for maintaining tumorigenicity in GSCs. Palmitoylation mediated by ZDHHC17 was indispensable for preserving Oct4A from lysosome degradation to maintain its protein stability. Oct4A palmitoylation also helped to integrate Sox4 and Oct4A in the SOX2 enhancement subregion to maintain the stem performance of GSCs. We also designed Oct4A palmitoylation competitive inhibitors, inhibiting the self-renewal ability and tumorigenicity of GSCs. CONCLUSIONS: These findings indicate that Oct4A acts on the tumorigenic activity of glioblastoma, and Oct4A palmitoylation is a candidate therapeutic target.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Chen X, Niu W, Fan X, et al. Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells. Neuro Oncol. 2023. PMID: 35727735. doi:10.1093/neuonc/noac157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。